Biomedicine & Pharmacotherapy最新文献

{"title":"Corrigendum to “Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin” [Biomed. Pharmacother. 173 (2024) 116360]","authors":"Zhenzhen Deng , Suo Qishan , Quanbin Zhang , Jing Wang , Yang Yue , Lihua Geng , Ning Wu","doi":"10.1016/j.biopha.2026.119213","DOIUrl":"10.1016/j.biopha.2026.119213","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119213"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Bioactive compounds and their libraries: An insight into prospective phytotherapeutics approach for oral mucocutaneous cancers\" [Biomedicine & Pharmacotherapy 141 (2021) 111809]","authors":"Henry A. Adeola , Afsareen Bano , Ravina Vats , Amit Vashishtha , Deepika Verma , Deepak Kaushik , Vineet Mittal , Md. Habibur Rahman , Agnieszka Najda , Ghadeer M. Albadrani , Amany A. Sayed , Sameh M. Farouk , Emad H.M. Hassanein , Muhammad Furqan Akhtar , Ammara Saleem , Mohamed M. Abdel-Daim , Rashmi Bhardwaj","doi":"10.1016/j.biopha.2026.119209","DOIUrl":"10.1016/j.biopha.2026.119209","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119209"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development\" [Biomedicine & Pharmacotherapy 162 (2023) 114574]","authors":"Meng-Lan Luo , Qian Zhao , Xiang-Hong He , Xin Xie , Hong-Ping Zhu , Feng-Ming You , Cheng Peng , Gu Zhan , Wei Huang","doi":"10.1016/j.biopha.2026.119210","DOIUrl":"10.1016/j.biopha.2026.119210","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119210"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage extracellular traps in autoimmunity: In vivo definition, pathogenic circuits, and therapeutic targeting","authors":"Mengchao Liu ,&nbsp;Mingzhe Wang ,&nbsp;Haoran Dai ,&nbsp;Hanxue Jiang ,&nbsp;Wenbin Liu ,&nbsp;Xiaoyu Cui ,&nbsp;Xinyue Tang ,&nbsp;Qihan Zhao ,&nbsp;Yuehong Hu ,&nbsp;Na Zhang ,&nbsp;Naiqian Zhang ,&nbsp;Baoli Liu ,&nbsp;Hongliang Rui","doi":"10.1016/j.biopha.2026.119180","DOIUrl":"10.1016/j.biopha.2026.119180","url":null,"abstract":"<div><div>Although neutrophil extracellular traps are well documented in autoimmune diseases, the pathogenic relevance of macrophage extracellular traps (METs) has been less well defined. METs are chromatin-based extracellular scaffolds that extend beyond antimicrobial defense to organize inflammation, concentrate danger signals, and externalize autoantigens. Accumulating preclinical and clinical evidence links increased MET burden to autoimmune activity and organ injury, consistent with a potential disease-amplifying contribution in selected contexts rather than a mere epiphenomenon. By exposing a broad antigenic repertoire—including modified chromatin (e.g., citrullinated histones in specific contexts) and mitochondrial DNA, METs may contribute to hallmark autoantibody responses such as ACPA, anti-dsDNA, and ANCA, and may sustain nucleic-acid–driven inflammatory programs. In this review, we conceptualize METs as a candidate integrative innate immune module that connects autoantigen presentation with fibro-inflammatory remodeling across rheumatoid arthritis, systemic lupus erythematosus, ANCA-associated vasculitis, and ulcerative colitis. We further propose a pragmatic in vivo identification and reporting checklist to reduce NET/MET misclassification and improve cross-study comparability. Finally, we outline three therapeutic axes—limiting MET induction, accelerating scaffold dismantling/clearance, and dampening DNA-sensing—and discuss translational constraints (host-defense trade-offs and biomarker-guided selection). Together, this synthesis provides a framework to prioritize mechanistic questions and accelerate biomarker and drug-development efforts targeting MET-driven pathology.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119180"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lysophosphatidylcholine as a mechanistic and therapeutic nexus in atherosclerotic cardiovascular disease","authors":"Ting-Chieh Lai ,&nbsp;Shao-Chi Hung ,&nbsp;Hua-Chen Chan ,&nbsp;Chih-Sheng Chu ,&nbsp;Gopal Kedihithlu Marathe ,&nbsp;Guenter Schwarz ,&nbsp;Liang-Yin Ke","doi":"10.1016/j.biopha.2026.119069","DOIUrl":"10.1016/j.biopha.2026.119069","url":null,"abstract":"<div><div>Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide despite intensive lipid-lowering therapy. Residual cardiovascular risk persists even in patients achieving optimal lipoprotein-cholesterol (LDL-C) levels, indicating that additional lipid mediators contribute to disease progression. Lysophosphatidylcholine (LPC), a bioactive lysophospholipid generated from phosphatidylcholine by cytosolic or lipoprotein-associated phospholipase A₂ (PLA₂), has emerged as a critical mediator linking dyslipidemia, inflammation, and vascular injury. LPC is highly enriched in oxidized LDL (oxLDL), electronegative LDL (LDL(−)), and lipoprotein(a) [Lp(a)], all of which represent highly atherogenic lipoprotein subclasses. This review delineates the metabolic origins of LPC, its transport via LDL, VLDL, and albumin, and its accumulation within atherosclerotic plaques. LPC promotes endothelial dysfunction, monocyte recruitment, foam-cell formation, and platelet activation, collectively driving plaque development and instability. Elevated LPC levels are consistently observed in metabolic disorders such as type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH), both of which exacerbate ASCVD risk. Although statins, ezetimibe, and PCSK9 inhibitors effectively lower LDL-C, they do not directly target LPC or its downstream inflammatory pathways. Clinical trials of lipoprotein-associated PLA₂ inhibitors (e.g., Darapladib) failed to reduce cardiovascular events, underscoring the complexity of LPC-related signaling. Future therapeutic approaches may involve enhancing lysophospholipase A₁ activity or selectively inhibiting LPC production to restore vascular homeostasis. In aggregate, LPC represents a mechanistic bridge between lipid metabolism, vascular inflammation, and thrombosis, underscoring its potential as a biomarker and therapeutic target for residual ASCVD risk.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119069"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147358094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of naphthyl derivatives on cell physiology of human leukaemia cells: Survival, cell cycle arrest and apoptosis","authors":"Emília P.T. Leitão ,&nbsp;Henoc del Rosario ,&nbsp;Inmaculada Hernández ,&nbsp;Ignacio González ,&nbsp;José Quintana ,&nbsp;Ester Saavedra ,&nbsp;Francisco Estévez ,&nbsp;Patricia Rijo","doi":"10.1016/j.biopha.2026.119155","DOIUrl":"10.1016/j.biopha.2026.119155","url":null,"abstract":"<div><div>By 2030, the incidence of new cases of cancer worldwide is expected to have increased by 18.1%, with a 22% increase in mortality. Leukaemia is the most common childhood cancer, and drug resistance remains a major therapeutic challenge. Many factors contribute to drug resistance, including inhibition of apoptotic cell death. Natural product-based drugs have led to significant advances in the treatment of human cancer. Due to their polyphenol structure, flavonoids exhibit various pharmacological properties, including antitumor activities. Here we evaluated the effects of twenty compounds including naphthyl chalcones and intermediates of flavones on viability of human leukaemia cells. Seven compounds showed growth inhibition against HL-60, U-937, MOLT-3, JURKAT, NALM-6 and the overexpressing Bcl-2 protein U-937/Bcl-2. Almost all IC₅₀ values were below 10 µM, and, for HL-60 and U937, the naphthyl ester <strong>6c</strong> and the naphthyl diketone <strong>8a</strong> compounds showed IC₅₀ values that were very similar to the standard therapeutic drug etoposide. Treatment of HL-60 and U-937 with <strong>6c</strong> and <strong>8a</strong> caused an increase in the percentage of sub-G₁ cells, G₂-M cell cycle phase arrest, activation and processing of caspases, poly(ADP-ribose) polymerase cleavage and cytochrome <em>c</em> release from mitochondria. Moreover, cell death was partially blocked by the general inhibitor of caspases z-VAD-fmk. Interestingly, the overexpression of Bcl-2 did not prevent U-937/Bcl-2 cells from dying.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119155"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnane X receptor antagonist MI-891 reduces hepatic triglycerides in PXR-CAR-CYP3A4/3A7-humanized mice","authors":"Klára Dohnalová ,&nbsp;Rajamanikkam Kamaraj ,&nbsp;Martin Ambrož ,&nbsp;Kryštof Klíma ,&nbsp;Karel Chalupský ,&nbsp;Mária Bajnoková ,&nbsp;Ivana Mejdrová ,&nbsp;Kryštof Škach ,&nbsp;Jana Hricová ,&nbsp;Hana Laštůvková ,&nbsp;Lucie Smutná ,&nbsp;Dharani Sai Sreekanth Nellore ,&nbsp;Radislav Sedláček ,&nbsp;Stanislav Mičuda ,&nbsp;Radim Nencka ,&nbsp;Petr Pavek","doi":"10.1016/j.biopha.2026.119168","DOIUrl":"10.1016/j.biopha.2026.119168","url":null,"abstract":"<div><div>Hepatic steatosis is a major metabolic concern associated with activation of the pregnane X receptor (PXR), a nuclear receptor known to promote lipogenesis and lipid accumulation in the liver. While the lipogenic effects of PXR agonists are well documented, there is no comprehensive data on the metabolic consequences of PXR inhibition. Here, we evaluated the impact of MI-891, a novel human PXR antagonist and inverse agonist, on hepatic lipid metabolism in high-fat diet (HFD)-fed PXR-CAR-CYP3A4/3A7-humanized female mice. Lipidomic analysis revealed a significant reduction in hepatic triglyceride levels and a shift in their saturation profile after MI-891 treatment. In parallel, RT-qPCR analysis showed a down-regulation of lipogenic genes (<em>Scd1</em>, <em>Thrsp</em>, <em>Acaca</em>) and lipid-droplet-associated genes (<em>Plin2</em>, <em>Hsd17b13</em>), suggesting suppressed fatty acid and triglyceride synthesis and diminished lipid droplet storage. The primary PXR target gene <em>CYP3A4</em> was downregulated at both the mRNA and protein levels, confirming PXR inhibition <em>in vivo</em>. Our findings demonstrate that MI-891 treatment effectively inhibits PXR activity and leads to significant alterations in the hepatic lipidome and lipid metabolism under HFD conditions. This study represents the first report of liver lipidomics in response to a PXR inhibitor, highlighting PXR inhibition as a potential therapeutic approach for hepatic steatosis.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119168"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Pipecolic acid mitigates ferroptosis in diabetic retinopathy by regulating GPX4-YAP signaling\" [Biomedicine & Pharmacotherapy 169 (2023) 115895]","authors":"Liying Luo ,&nbsp;Yuying Cai ,&nbsp;Yanyun Jiang ,&nbsp;Yingying Gong ,&nbsp;Chunyang Cai ,&nbsp;Dongwei Lai ,&nbsp;Xiao Jin ,&nbsp;Zhiqiang Guan ,&nbsp;Qinghua Qiu","doi":"10.1016/j.biopha.2026.119178","DOIUrl":"10.1016/j.biopha.2026.119178","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119178"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Decrypting the circular RNAs does a favor for us: Understanding, diagnosing and treating diabetes mellitus and its complications\" [Biomedicine & Pharmacotherapy 168 (2023) 115744]","authors":"Zi Li ,&nbsp;Yuanyuan Ren ,&nbsp;Ziwei Lv ,&nbsp;Man Li ,&nbsp;Yujia Li ,&nbsp;Xiaobin Fan ,&nbsp;Yuyan Xiong ,&nbsp;Lu Qian","doi":"10.1016/j.biopha.2026.119163","DOIUrl":"10.1016/j.biopha.2026.119163","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119163"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “The emergence of metal oxide nanoparticles (NPs) as a phytomedicine: A two-facet role in plant growth, nano-toxicity and anti-phyto-microbial activity” [Biomedicine & Pharmacotherapy 155 (2022) 113658]","authors":"Rahul Bhattacharjee ,&nbsp;Lamha Kumar ,&nbsp;Nobendu Mukerjee ,&nbsp;Uttpal Anand ,&nbsp;Archna Dhasmana ,&nbsp;Subham Preetam ,&nbsp;Samudra Bhaumik ,&nbsp;Sanjana Sihi ,&nbsp;Sanjana Pal ,&nbsp;Tushar Khare ,&nbsp;Soham Chattopadhyay ,&nbsp;Sally A. El-Zahaby ,&nbsp;Athanasios Alexiou ,&nbsp;Eapen P. Koshy ,&nbsp;Vinay Kumar ,&nbsp;Sumira Malik ,&nbsp;Abhijit Dey ,&nbsp;Jarosław Proćków","doi":"10.1016/j.biopha.2026.119196","DOIUrl":"10.1016/j.biopha.2026.119196","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119196"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}